|
US7666400B2
(en)
*
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7550143B2
(en)
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US7878978B2
(en)
|
2004-03-18 |
2011-02-01 |
University Of Pittsburgh- Of The Commonwealth System Of Higher Education |
Use of relaxin to increase arterial compliance
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
AU2006232920B2
(en)
|
2005-04-06 |
2011-09-29 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US8883162B2
(en)
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
AU2006302848C1
(en)
*
|
2005-10-19 |
2012-08-02 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
WO2012024223A2
(en)
*
|
2010-08-17 |
2012-02-23 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
|
EA201500156A3
(ru)
|
2008-01-03 |
2017-09-29 |
Дзе Скриппс Рисерч Инститьют |
Доставка антител посредством модульного домена распознавания
|
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
|
BRPI0911427A2
(pt)
*
|
2008-04-10 |
2015-11-17 |
Ibc Pharmaceuticals |
complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica.
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
CA2734265C
(en)
|
2008-08-20 |
2017-12-19 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
WO2010028796A1
(en)
*
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Trispecific hexavalent antibodies
|
|
US8535477B2
(en)
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
EP2995953B1
(en)
*
|
2009-03-24 |
2017-11-29 |
Biocept, Inc. |
Devices and methods of cell capture and analysis
|
|
US20120100538A1
(en)
|
2009-03-24 |
2012-04-26 |
Biocept, Inc. |
Devices and methods of cell capture and analysis
|
|
EP2473186A4
(en)
*
|
2009-08-31 |
2013-07-10 |
Ibc Pharmaceuticals Inc |
BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF
|
|
EP2473187A4
(en)
*
|
2009-08-31 |
2015-09-16 |
Immunomedics Inc |
COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
|
|
CA2776563A1
(en)
*
|
2009-11-05 |
2011-05-12 |
Center For Molecular Medicine And Immunology |
Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
|
|
EP2509630A4
(en)
*
|
2009-12-09 |
2013-07-17 |
Immunomedics Inc |
SYSTEM FOR PROCESSING CYTOTOXIC REMEDIES THROUGH BISPECIFIC ANTIBODY TARGET
|
|
CN102665758A
(zh)
|
2009-12-09 |
2012-09-12 |
Ibc药品公司 |
用于递送干扰rna的对接锁定(dnl)复合物
|
|
AU2011235328A1
(en)
*
|
2010-04-01 |
2012-09-27 |
Immunomedics, Inc. |
Antibody-based depletion of antigen-presenting cells and dendritic cells
|
|
EP2588525A4
(en)
|
2010-06-29 |
2015-06-10 |
Covidien Lp |
MICROWAVE POWERED REACTOR AND IN SITU IMPLANT TRAINING METHOD
|
|
US8865857B2
(en)
|
2010-07-01 |
2014-10-21 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
MX2013004202A
(es)
*
|
2010-10-20 |
2013-10-17 |
Morphotek Inc |
Glicoformas de anticuerpos anti-receptores de folato alfa.
|
|
AU2011323354B2
(en)
*
|
2010-11-03 |
2014-07-31 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
EP2704751B1
(en)
*
|
2011-05-02 |
2019-04-17 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
LT2748202T
(lt)
*
|
2011-08-23 |
2018-09-25 |
Roche Glycart Ag |
Bispecifinės antigeną surišančios molekulės
|
|
EP3321286B1
(en)
*
|
2011-08-23 |
2021-01-06 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
US20130058936A1
(en)
*
|
2011-08-23 |
2013-03-07 |
Peter Bruenker |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
WO2013026837A1
(en)
*
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
EP2748613B1
(en)
|
2011-10-07 |
2021-05-05 |
Baxalta GmbH |
Oxmif as a diagnostic marker
|
|
AU2013202693B2
(en)
*
|
2012-04-16 |
2015-01-22 |
Baxalta GmbH |
Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
|
|
CN104363919A
(zh)
*
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
KR102006997B1
(ko)
*
|
2012-07-03 |
2019-08-02 |
한국생명공학연구원 |
ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자
|
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
JP6444874B2
(ja)
|
2012-10-08 |
2018-12-26 |
ロシュ グリクアート アーゲー |
２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
|
|
FR3003172B1
(fr)
*
|
2013-03-15 |
2017-12-08 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
|
WO2014131694A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
PE20151410A1
(es)
|
2013-02-26 |
2015-09-18 |
Roche Glycart Ag |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
US9416197B2
(en)
|
2013-11-01 |
2016-08-16 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
|
|
US10605810B2
(en)
|
2013-12-30 |
2020-03-31 |
University-Industry Cooperation Group Of Kyung Hee University |
Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof
|
|
CN113549153A
(zh)
|
2014-05-29 |
2021-10-26 |
宏观基因有限公司 |
三特异性结合分子和其使用方法
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
PL3177643T3
(pl)
|
2014-08-04 |
2019-09-30 |
F.Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
|
|
CN107484416A
(zh)
|
2014-09-26 |
2017-12-15 |
宏观基因有限公司 |
能够结合cd19和cd3的双特异性单价双抗体及其用途
|
|
LT3221355T
(lt)
|
2014-11-20 |
2020-12-28 |
F. Hoffmann-La Roche Ag |
Kombinuotoji t ląsteles aktyvinančių bispecifinių antigeną surišančių molekulių cd3 bei folato receptoriaus 1 (folr1) ir pd-1 ašą surišančių antagonistų terapija
|
|
WO2016079076A1
(en)
|
2014-11-20 |
2016-05-26 |
F. Hoffmann-La Roche Ag |
T cell activating bispecific antigen binding molecules agiant folr1 and cd3
|
|
PT3221357T
(pt)
|
2014-11-20 |
2020-07-28 |
Hoffmann La Roche |
Cadeias leves comuns e métodos de utilização
|
|
SG11201705323WA
(en)
*
|
2015-01-16 |
2017-07-28 |
Academia Sinica |
Molecular constructs with targeting and effector elements
|
|
RU2017129236A
(ru)
|
2015-01-26 |
2019-03-07 |
Макродженикс, Инк. |
Мультивалентные молекулы, содержащие dr5-связывающие домены
|
|
KR20220018081A
(ko)
*
|
2015-03-04 |
2022-02-14 |
아이쥐엠 바이오사이언스 인코포레이티드 |
Ｃｄ20 결합 분자 및 그의 용도
|
|
CN104829730A
(zh)
*
|
2015-04-14 |
2015-08-12 |
苏静 |
一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
|
|
WO2016191481A1
(en)
|
2015-05-28 |
2016-12-01 |
Immunomedics, Inc. |
T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
NZ737726A
(en)
*
|
2015-07-06 |
2023-03-31 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
EP3322716B1
(en)
*
|
2015-07-15 |
2025-02-12 |
California Institute of Technology |
Il-17f-specific capture agents and methods of using
|
|
SMT202100527T1
(it)
|
2015-07-30 |
2021-11-12 |
Macrogenics Inc |
Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
BR112018006817A2
(pt)
|
2015-10-08 |
2018-10-23 |
Macrogenics Inc |
método de tratamento do câncer
|
|
MX2018005229A
(es)
|
2015-12-09 |
2019-04-29 |
F HoffmannLa Roche Ag |
Anticuerpo anti-cd20 de tipo ii y usos del mismo.
|
|
MX2018007089A
(es)
|
2015-12-14 |
2019-01-30 |
Macrogenics Inc |
Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
|
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
|
US20170233472A1
(en)
|
2016-02-17 |
2017-08-17 |
Macrogenics, Inc. |
ROR1-Binding Molecules, and Methods of Use Thereof
|
|
ES2947230T3
(es)
|
2016-03-22 |
2023-08-03 |
Hoffmann La Roche |
Moléculas biespecíficas para linfocitos T activadas por proteasa
|
|
MY198114A
(en)
|
2016-04-15 |
2023-08-04 |
Macrogenics Inc |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
JP7022123B2
(ja)
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３に対する二重特異性抗体
|
|
KR102630036B1
(ko)
|
2016-12-23 |
2024-01-29 |
마크로제닉스, 인크. |
Adam9-결합 분자, 및 이것의 사용 방법
|
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
EP3589316B1
(en)
*
|
2017-02-28 |
2024-08-07 |
Affimed GmbH |
Combination of an anti-cd16a antibody with a cytokine
|
|
GB201705686D0
(en)
*
|
2017-04-07 |
2017-05-24 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
AR111651A1
(es)
*
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
JP7348844B2
(ja)
|
2017-06-07 |
2023-09-21 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
内部移行酵素のための組成物および方法
|
|
WO2019010224A1
(en)
|
2017-07-03 |
2019-01-10 |
Torque Therapeutics, Inc. |
FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND USES THEREOF
|
|
KR20200098590A
(ko)
|
2017-12-12 |
2020-08-20 |
마크로제닉스, 인크. |
이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
|
|
SG11202007363TA
(en)
|
2018-02-07 |
2020-08-28 |
Regeneron Pharma |
Methods and compositions for therapeutic protein delivery
|
|
SG11202007390YA
(en)
|
2018-02-08 |
2020-08-28 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
|
MX2020008489A
(es)
|
2018-02-15 |
2020-09-25 |
Macrogenics Inc |
Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
|
|
US12252544B2
(en)
|
2018-05-17 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-CD63 antibodies, conjugates, and uses thereof
|
|
US12435155B2
(en)
|
2020-02-21 |
2025-10-07 |
Macrogenics, Inc. |
CD137 binding molecules and uses thereof
|
|
JP7741111B2
(ja)
|
2020-06-19 |
2025-09-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３及びｃｄ１９に結合する抗体
|
|
EP4175650A1
(en)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
CN111848462B
(zh)
*
|
2020-08-14 |
2021-05-11 |
上海大学 |
一种芘磺酸盐衍生物及其制备方法和应用
|
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
CN112553256B
(zh)
*
|
2021-02-20 |
2021-06-22 |
北京百普赛斯生物科技股份有限公司 |
Il-2受体复合物及其制备方法与应用
|
|
JP2024517535A
(ja)
|
2021-04-30 |
2024-04-23 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体と抗ｃｄ７９ｂ抗体薬物コンジュゲートを用いた併用治療の投与
|
|
CN113533272B
(zh)
*
|
2021-06-26 |
2024-01-09 |
浙江工商大学 |
一种提高时间分辨荧光信号强度的标记方法及应用
|
|
CN118541392A
(zh)
*
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|